Interview with Bingshen Li, CEO, SinoGenoMax
SinoGenoMax was founded in 1998 with the purpose of participating in the Human Genome Project. Could you give us an overview of the company’s activities since then and the transformation…
Address: No. 3-707 North Yongchang Road,BDA,Beijing 100176,P.R.China.,China
Tel: +86 10 6788 3332
Web: http://www.sinogenomax.com/en
As one of the largest genomics-based biotech companies in China, SinoGenoMax Co.,Ltd. was incorporated in September 1998 by a joint investment from the Beijing Municipal Science & Technology Commission and Beijing Boda Sci-Tech Venture Capital Ltd. Its founding members include the Chinese Academy of Medical Sciences, Peking University, the Chinese Academy of Science, and the Beijing Institute of Medical Sciences. The affililated institute, Chinese National Human Genome Center of Beijing (CHGB) was established in October 1998 at SinoGenoMax.
SinoGenoMax participated in the International Human Genome Sequencing Project, and has been closely involved in several major genome-related research projects such as pathogenic microorganism sequencing projects, Chinese population single nucleotide polymorphism (SNP) genotyping project, and other disease genome research projects.
Originally focused on DNA sequencing and analysis, SinoGenoMax has subsequently expanded its expertise in all aspects of molecular biology and protein biology. SinoGenoMax has built up several independent technical groups including genomics group, proteomics group, and molecular biology group. In particular, SinoGenoMax has perfected a rigorous quality-management system to implement process monitoring and quality control for all the procedures we perform. SinoGenoMax has passed the ISO 9001:2000 international certification of quality management system since 2004, and is now preparing to obtain ISO/IEC 17025:2005 accreditation of testing laboratory.
There are currently 100 employees working at SinoGenoMax located in Beijing Economic-Technological Development Area. SinoGenoMax’s 5,000 square meter laboratory building is fully equipped with top class facilities including DNA Sequencers, mass spectrometry, HPLC, Microarray Chip Reader, and lab automation workstation, for high throughput operation and analysis in genomics and proteomics research. A proprietary Laboratory Information Management System(LIMS) has been implemented for standardized management of samples,data and work flow, and all procedures are performed under the guidance of corresponding SOPs.
In the past few years, SinoGenoMax has successfully provided high quality and cost-effective services for several international pharmaceutical companies. Whether in the scientific research or industrial of production, the widely recognized achievements have enabled SinoGenoMax to become the best biotechnology service company at home and abroad.
Large-scale DNA sequencing, Bioinformatics, Protein expression & Purification, Protein Seperation & Identification, Antibody Production, Functional Genomics & Drug Disc. Platform, Genome-Based Target Validation, Pathway-Based Target Validation, siRNA-Based Drug Screening
SinoGenoMax was founded in 1998 with the purpose of participating in the Human Genome Project. Could you give us an overview of the company’s activities since then and the transformation…
Dr Li Shuai of pain- and CNS-focused Chinese biotech SIMR outlines the history of the company, the unmet medical needs it is seeking to address, its partnership strategy, and the…
Zhenkun Ma, founder and CEO of TenNor Therapeutics, shares his cross-sectorial experiences in Big Pharma, biotech and non-profit organization that led to the establishment of TenNor Therapeutics; their mission to…
The US FDA has granted orphan drug designation to Shanghai-headquartered biotech CARsgen Therapeutics’ CAR-T cell therapy CT053 for multiple myeloma after positive results were observed in the phase I trial…
Competition is heating up among Asian stock exchanges hoping to lure the hottest prospects in Chinese biotech to list there. The newest competitor, Shanghai’s STAR Board, has already attracted over…
Earlier this year, PharmaBoardroom highlighted five of the most innovative and important biotech companies making waves in the world’s second-largest pharmaceutical market, China. Here, we pick out five more firms looking…
Dr Kai Lamottke, co-founder and MD of Bicoll GmbH, Munich, and since 2001, GM and board member of Bicoll Biotechnology (Shanghai) Co. Ltd discusses Bicoll’s presence in both the Chinese…
Jim Xu, GM of Medidata China, shares the importance of the China market to Medidata Solutions, the global leader in cloud services and solutions to the life sciences industry; his…
Dr. Chris Lu, CEO and cofounder of Laekna Therapeutics, shares Laekna’s ambition to deliver cures and improve the quality of life of patients globally, captured by the word ‘Laekna’, which…
Tony Acciarito, President of Thermo Fisher Scientific China, explains how he is delivering the company’s mission of ‘enabling our customers to make the world healthier, cleaner and safer’ in China,…
Zheru Zhang and Jielun Zhu of I-Mab Biopharma, shares their vision for the ambitious biotech company looking to develop their dual-pronged strategy of in-licensing ‘fast-to-market’ assets for their China portfolio…
Junshi Biosciences is an innovation-driven biopharmaceutical company with a focus on discovery and innovative drugs. Dr Li Ning, CEO, discusses being the first Chinese company to successfully launch a domestically-developed…
Kai Zhang, founder and chairman, and Sonia Wang, CEO, of Chinese respiratory technology specialist Omni Pharmaceuticals, discuss the respiratory market in China, how Omni plans to introduce four respiratory drugs…
See our Cookie Privacy Policy Here